BlossomHill Therapeutics filed for an IPO to raise about $111.7 million, earmarking funding for a potential Tagrisso challenger and additional early pipeline programs. The company’s lead asset, BH-30643, is in Phase 1/2 in NSCLC, with plans for a potentially registrational Phase 2 study supported by IPO proceeds. BlossomHill also intends to push BH-30236 through a Phase 1 study and advance BH-501284 from IND-enabling studies, positioning the company across multiple therapeutic targets. The filing underscores how emerging oncology biotechs are using capital markets to accelerate clinical sequencing in competitive biomarker-defined categories.